Notably, with the advent of novel drug classes such as GLP-1 RA and SGLT2i, the pharmacological approach to PAD in T2D might undergo—and probably already underwent—a significant watershed due to their CV benefits. This evidence concerns the gene GCG and peripheral arterial disease.